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ABSTRACT
Epididymal protease inhibitor (eppin [official symbol,
SPINLW1]) is of interest as a male contraceptive target because
of its specificity and location on the human sperm surface. We
have examined the effect of anti-eppin antibodies from infertile
male monkeys and the effect of recombinant human semenoge-
lin on human sperm motility. Anti-eppin antibodies significantly
decreased the progressive motility of human spermatozoa as
measured by decreased total distance traveled, decreased
straight-line distance, and decreased velocity. Anti-eppin treat-
ment of spermatozoa significantly increased the amount of
cAMP present in nonprogressive spermatozoa; however, ap-
proximately 25% of antibody-treated spermatozoa could be
rescued by the addition of cAMP-acetoxymethyl ester, indicating
that anti-eppin-treated spermatozoa have a compromised ability
to utilize cAMP. Addition of recombinant human semenogelin
has a concentration-dependent inhibitory effect on progressive
motility (increased tortuosity and decreased velocity). We tested
the hypothesis that anti-eppin antibodies bound to eppin would
subsequently block semenogelin binding to eppin. Anti-eppin
antibodies from infertile monkeys inhibited eppin from binding
to semenogelin. Addition of affinity-purified antibodies made to
the dominant C-terminal epitope of eppin had an inhibitory
effect on progressive motility (increased tortuosity, decreased
velocity, and straight distance). Our results suggest that the
eppin-semenogelin binding site is critical for the removal of
semenogelin in vivo during semen liquefaction and for the
initiation of progressive motility. We conclude that the eppin-
semenogelin binding site on the surface of human spermatozoa
is an ideal target for a nonsteroidal male contraceptive.
cAMP, contraception, eppin, gamete biology, semenogelin,
seminal plasma, sperm, spermatozoa
INTRODUCTION
Eppin (epididymal protease inhibitor [official symbol,
SPINLW1]) is of interest as a male contraceptive target
because of its specificity and location on the human sperm
surface. Previous work on eppin demonstrated that male
monkeys immunized with recombinant human eppin to a high
serum titer (.1:1000) and sustained over several months
achieved an effective level of contraception (100%) that was
reversible [1]. Contraceptive investigations in nonhuman
primates demonstrated that eppin has an essential role in
fertility and provided the first observations of reduced sperm
motility that coincided with the appearance of an anti-eppin
titer in the semen (see Fig. S3 [monkey sample no. 28309] in
Supporting Online Material in O’Rand et al. [1]).
Eppin is a member of the whey acidic protein (WAP)-type
four-disulfide core gene family located in a telomeric cluster on
human chromosome 20q12-q13 and is the archetype of WFDC
genes characterized by encoding Kunitz-type and WAP-type
four-disulfide core protease inhibitor consensus sequences [2].
The eppin protein is specific to male reproductive tissue;
secreted by Sertoli cells and epididymal epithelial cells [2, 3],
eppin becomes localized on the surface of ejaculated
spermatozoa in a complex of proteins containing lactotrans-
ferrin, clusterin, and semenogelin [3]. The eppin protein
complex [3, 4] modulates prostate-specific antigen (PSA)
protease activity [5] and provides antimicrobial protection for
spermatozoa in the ejaculate coagulum [6]. Activated PSA
cleaves semenogelin by hydrolysis immediately after ejacula-
tion, liquefying the coagulum [7] and freeing the spermatozoa
for motility and capacitation [8, 9].
To understand the essential role of eppin in fertility, we have
conducted investigations on eppin function, which led to the
demonstration that in seminal plasma eppin is bound to
semenogelin I [4] and that on human spermatozoa following
ejaculation eppin is present in a protein complex [3]. Moreover,
the mechanism of action of the anti-eppin antibody seems to be
to prevent normal eppin-semenogelin interaction [5], subse-
quently inhibiting the motility of ejaculate spermatozoa. To
extend these observations to human spermatozoa, we have
examined the effect of anti-eppin antibodies from infertile male
monkeys [1], as well as the effect of recombinant human
semenogelin (SEMG1) on human sperm motility. The
contraceptive anti-eppin antibodies cause inhibition of pro-
gressive motility, which could be rescued in approximately
25% of antibody-treated spermatozoa by the addition of
cAMP-acetoxymethyl ester (cAMP-AM). Our results suggest
that the eppin-semenogelin binding site is critical for the
removal of semenogelin from spermatozoa in vivo during
semen liquefaction and for the initiation of progressive
motility. These observations identify an ideal target on the
surface of human spermatozoa, namely, the eppin-semenogelin
binding site, for a nonsteroidal male contraceptive.
MATERIALS AND METHODS
Reagents and chemicals were molecular biology grade purchased from
Sigma-Aldrich (St. Louis, MO). Human semen samples were obtained from the
Department of Obstetrics and Gynecology, University of North Carolina at
Chapel Hill, and this study was approved by the Committee on the Protection
of the Rights of Human Subjects at the School of Medicine, University of North
Carolina at Chapel Hill. Affinity-purified rabbit antibodies to the C-terminal of
eppin (amino acids 103–123) were produced by Bethyl Laboratories, Inc.
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(Montgomery, TX) to the peptide SMFVYGGAQGNNNNFQSKANC (anti-
body S21C), in which alanine was substituted for cysteine 110. Student t-test
was used to test the null hypothesis that the means of the two populations are
equal.
Preparation of Spermatozoa
Semen samples were collected from fertile donors at the UNC North
Carolina Memorial Hospital infertility clinic, allowed to liquefy for 30 min, and
given a standard semen analysis to determine acceptability as an anonymous
semen donor. Samples from acceptable donors were frozen immediately in test-
yolk buffer and stored in liquid nitrogen. Samples for study were thawed at
378C, washed twice in 378C sperm washing medium (modified human tubal
fluid; Irvine Scientific, Santa Ana, CA), and collected by centrifugation at 300
3 g for 5 min, and the supernatant was removed. A 1-ml aliquot of 378C
medium containing 25 mM sodium bicarbonate (M16; Sigma) was layered over
the pellet, and spermatozoa were allowed to ‘‘swim up’’ into the medium in a
CO
2
incubator. After 1 h, the M16 supernatant layer was removed and
centrifuged at 300 3 g for 5 min to collect the spermatozoa. Aliquots of the
swim-up population were taken to determine percentage motility and sperm
concentration.
Analysis of Sperm Motility
The objective of this study was to determine the change in progressive
sperm motility in control and treated experimental groups of swim-up
spermatozoa. Therefore, we used the following experimental parameters. For
motility analysis, a 5-ll aliquot of the swim-up sperm sample was evenly
distributed in a 20-lm glass chamber slide (Leja Products B.V., Nieuw Vennep,
The Netherlands) and viewed immediately (within 3 min) with a Plan-
Apochromat 203/0.8 phase 2 (diameter width, 0.55 mm) objective or a Plan-
Neofluar 103/0.3 phase 1 objective on a Zeiss Axiophot microscope (all from
Carl Zeiss, Thornburg, NY). At least four random fields in each chamber were
selected, and sperm motility was recorded with an AxioCam HSc high-speed
camera (Carl Zeiss). Recordings were for 1 sec at frame rates varying from 60
to 103 frames/sec and with pixel windows varying from 660 3 492 to 328 3
248, depending on the experiment. In some experiments, recordings were also
made with an AxioCam MRc high-speed charge-coupled device camera (Zeiss)
for 10 or 15 sec at frame rates varying from 6 to 18 frames/sec and with pixel
windows varying from 1300 3 1030 to 256 3 256. Sperm tracks were analyzed
with Zeiss Cell Observer time-lapse and tracking software (AxioVs40 V4.6.3.0;
Carl Zeiss). As many sperm as possible were tracked in each field, with a total
of 25–100 tracks analyzed from semen samples from at least two different
donors for any experimental determination. Although these cameras and the
analysis software do not provide the same motion analysis as a computer-aided
sperm analysis system (limited to 60 frames/sec), they allow more flexibility for
high-resolution observation of the forward-swimming progression of individual
sperm over longer times and distances, with variable frame rates and pixel
window sizes.
Affinity Purification of Monkey Anti-Eppin Antibodies
Monkey anti-eppin antibodies were obtained during our previous study [1]
in which seven male monkeys immunized with recombinant human eppin were
found to be infertile. As indicated in our previous study, these antibodies were
obtained following protocols approved by our local Institutional Animal Care
and Use Committee and by the Committee for the Purpose of Control and
Supervision of Experiments on Animals, New Delhi, India. The serum from
each male monkey was heat inactivated at 608C for 40 min and precipitated
with 40% ammonium sulfate. Pellets were washed three times and dialyzed into
PBS (pH 7.4). Eppin affinity beads were made in bulk by binding His-tagged
eppin to Ni2
þ
-affinity (NTA) resin (Qiagen, Valencia, CA) and by adding an
equal volume of Sephadex G-50 (Sigma) to improve flow rate and packing.





, 10 mM Tris-Cl, 8 M urea, pH 8.0) and buffer C (same as buffer B,
pH 6.3), followed by extensive washing in Tris-buffered saline (TBS) (50 mM
Tris [pH 7.4] and 150 mM NaCl). An aliquot of ammonium sulfate-precipitated
monkey preimmune serum was applied to the beads to block nonspecific
binding, and beads were washed again in TBS. Aliquots of these beads were
taken to affinity purify each monkey’s serum separately. Ten milligrams of
each monkey’s serum was applied to an aliquot of the eppin-Ni-NTA beads and
washed with TBS. Anti-eppin antibodies were eluted with IgG elution buffer
(Pierce, Rockford, IL), dialyzed in PBS, and concentrated. The following sera
from the previous study [1] were used: group 1 (squalene adjuvant [Day 523
sera] in monkey sample nos. 602, 619, 625, and 679) and group 2 (complete
Freund adjuvant [Day 145 sera] in monkey sample nos. 610, 656, and 657).
Preimmune serum from monkey sample no. 656 was used for the control and
was prepared as IgG. The protein concentration of each antibody was
determined and adjusted so that they were all approximately equal (mean 6
SD, 0.9 6 0.1 mg/ml). Human sperm were prepared as swim-up sperm and
assessed for forward motility. Only samples with .90% forward motility were
used in the assay. The sperm concentration was adjusted to ;2 3 106 sperm/ml.
Equal volumes of antibody (in the same buffer used for the spermatozoa) and
spermatozoa were mixed and incubated at 378C (5% CO
2
). Aliquots were taken
at various times to assess motility.
Cyclic AMP
Cyclic AMP levels were measured in spermatozoa using an AlphaScreen
cAMP assay kit (Perkin Elmer, Boston, MA) in a competitive immunoassay
between endogenous cAMP and exogenous biotinylated cAMP. Treated and
control spermatozoa were washed with PBS containing 0.5 mM 3-isobutyl-1-
methyl-xanthine (IBMX) (I5879; Sigma) and extracted in acidified ethanol, and
400-ll aliquots of supernatant were evaporated to dryness. Samples were
dissolved in 50 ll of stimulation buffer (13 Hanks balanced salt solution, 0.5
mM IBMX, 0.1% BSA, 5 mM Hepes), and the pH was adjusted to ;7 with 5
ll of 1 M Hepes. Readings were taken in a Biotek Synergy 2 Multimode
Microplate reader (Biotek Instruments, Winooski, VT). For reactivation
experiments, spermatozoa were loaded to a final concentration of 60 lM
cAMP-AM (Sigma) in 0.25% pluronic acid in M16 media [10].
TABLE 1. Percentage motility of human spermatozoa treated with affinity
purified anti-eppin antibodies from infertile male monkeys.a
Monkey sample no.
Motility range (%)b
0 min 30 min 60 min 120 min
0/656 (control) 100–75 100–75 100–75 100–75
145/610 100–75 100–75 100–75 25–0
145/656 100–75 100–75 50–25 25–0
145/657 100–75 100–75 75–50 0
523/602 100–75 100–75 25–0 0
523/619 100–75 100–75 25–0 0
523/625 100–75 75–50 50–25 50–25
523/679 100–75 100–75 75–50 0
a Sperm concentration ¼ 2.04 3 106 sperm/ml; all antibody-treated
spermatozoa completely or partially lost progressive motility by 120 min.
b Motility range was determined by counting .100 spermatozoa in each
of six randomly selected fields for each time point.















Total distance (lm) 131.4 6 36 111.4 6 41 78.96 6 58 1.99 3 103 71 6.26 3 1010
Straight distance (lm) 28.1 6 11 17.8 6 9 10.2 6 9 1.63 3 104 57 5.37 3 1025
Velocity (lm/sec) 131.7 6 38 117.7 6 44 83.4 6 61 1.99 3 103 71 3.96 3 108
Tortuosity 6.0 6 5 8.4 6 6 11.7 6 8 2.46 3 102 1.43 increase 1.74 3 106
a Sperm were treated with affinity purified anti-eppin antibody from monkey 523/619 or preimmune control IgG for 60 min; only spermatozoa with some
discernable movement were measured.
b N¼Number of tracks analyzed.
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Eppin-Semenogelin Binding Assay
Triplicate samples of antibody dilutions preincubated with 500 ng of
FLAG-eppin were applied to His-Select Nickel High Sensitivity 96-well plates
(Sigma) previously coated with 100 ng/well of His-SEMG1 (semenogelin) and
blocked in TBST (TBS þ 0.05% Tween 20/13 casein [Vector Laboratories,
Burlingame, CA]). After overnight incubation, plates were washed and
incubated with 1:1000 anti-FLAG M2 antibody followed by horseradish
peroxidase-labeled secondary antibody. The reaction was developed with TMB
substrate (tetramethylbenzidine; KPL, Gaithersburg, MD), stopped, and the
optical density (OD) was read at 450 nm. Positive controls for the assay
included preimmune sera and buffer only. In the absence of anti-eppin
antibodies, the assay gives an OD at 450 nm of approximately 1.0 6 0.1. In the
absence of FLAG-eppin, the assay gives an OD at 450 nm of approximately 0.2
6 0.1. Consequently, as the concentration of anti-eppin antibody increases, the
OD decreases.
RESULTS
Contraceptive anti-eppin antibodies from the seven infertile
eppin-immunized male monkeys [1] were purified on eppin
affinity columns and dialyzed against PBS, and their effect on
the progressive motility of human spermatozoa was evaluated.
All seven of the antibodies caused a loss of progressive motility
within 1 h after addition to the spermatozoa; the spermatozoa
began to swim more slowly and finally were unable to make
forward progress and only twitched in place. No agglutination
of spermatozoa was observed. Two hours after addition, four
samples completely stopped the forward progress of the
spermatozoa, two samples resulted in a reduction to 25%
motility, and 1 sample resulted in a reduction to 50% motility
(Table 1). Spermatozoa treated with preimmune control IgG
remained motile after 2 h.
FIG. 1. Video frames of human sperm
swimming patterns. A) Control spermatozoa
from a normal swim-up sample from a
fertile donor (still image from Supplemental
Movie 1 [movie is presented in black and
white]). Sperm tracks were recorded for 1
sec at 103 frames/sec with a 103 objective.
B) Spermatozoa treated with anti-eppin
antibodies from monkey sample no. 523/
619 (still image from Supplemental Movie 2
[movie is presented in black and white]).
Sperm tracks were recorded for 1 sec at 103
frames/sec with a 103 objective. C) Sper-
matozoa treated with anti-eppin antibodies
from monkey sample no. 523/602 without
cAMP-AM added. Sperm tracks were re-
corded for 10 sec at 7.4 frames/sec, 650 3
514 frame size, and no binning with a 103
objective. D) Spermatozoa treated with
anti-eppin antibodies from monkey sample
no. 523/602 with added cAMP-AM. Sperm
track was recorded for 10 sec at 7.4 frames/
sec, 650 3 514 frame size, and no binning
with a 103 objective. E) Spermatozoa
treated with recombinant semenogelin, 6.5
lg/106 sperm. Sperm tracks were recorded
1 h after treatment for 10 sec at 8 frames/sec
with a 103 objective. F) Control spermato-
zoa from a normal swim-up sample from a
fertile donor. Sperm tracks were recorded
for 10 sec at 8 frames/sec with a 103
objective. Each number represents a sperm
track as it is counted by the computer.









1.64 6 1.2 SD
Semenogelin (34)b 4.4 6 17.7 SD 0.3
Semenogelin (38)c 7.4 6 14.1 SD 0.0164
a Sperm were treated with M16 media.
b Sperm were treated with rSEMG1 (2.2 lg/106 sperm) for 60 min after
‘‘swim up’’ and evaluated for motility.
c Sperm were treated with rSEMG1 (6.5 lg/106 sperm) for 60 min after
‘‘swim up’’ and evaluated for motility.
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A more detailed analysis was undertaken using image
analysis software (Zeiss Cell Observer). Figure 1A shows a
typical video frame of human sperm-swimming patterns
(tracks) found in a normal swim-up sample from a fertile
donor. The field of view shows sperm tracks recorded for 1 sec
at 103 frames/sec with a 103 objective. To determine relative
forward-swimming progression, the tortuosity was calculated
[11] as the curvilinear distance:straight-line distance ratio of
the path. Fertile donor spermatozoa most often exhibited
progressive straight tracks, with slight circular trajectories, over
longer periods. Samples of spermatozoa measured at 103
frames/sec from sperm donors selected at random had a mean
6 SD tortuosity of 6.0 6 5.0 (range, 2.2–24.2; linearity, 17%;
n¼ 110). When measured at 8 frames/sec for 10 sec, samples
of spermatozoa from five semen donors selected at random had
a mean 6 SD tortuosity of 1.7 6 1.1 (range, 1.0–5.8; linearity,
59%; n ¼ 105). A tortuosity of 1.8 (linearity, 55%; n ¼ 205)
was measured for identical donor samples at 60 frames/sec
using a computer-aided sperm analysis system. These results
indicate that image sampling frequencies affect the values
measured, as reported previously [12–14]; however, normal
fertile spermatozoa exhibit identical swimming patterns
(progressive straight tracks with slight circular trajectories)
regardless of the number of frames per second.
Antibodies from the seven infertile eppin-immunized male
monkeys were analyzed using image analysis software for their
effect on sperm motility. Analysis was performed on each
sample, and a typical result from monkey sample no. 523/619
is given in Table 2 and in Figure 1B. Results were similar for
semen samples from several different donors. Compared with
the control (preimmune IgG), there was a significant difference
in the progressive motility of human sperm after treatment with
anti-eppin antibody as measured by a decrease in the relative
total distance traveled by 71% (P¼ 1.99 3 103), a decrease in
the relative straight-line distance by 57% (P ¼ 1.63 3 104),
and a decrease in the velocity by 71% (P ¼ 1.99 3 103). As
shown in Table 2, the antibodies have the effect of decreasing
the progressive motility; as progressive distance decreases,
tortuosity increases by 39% (P ¼ 2.46 3 102). Figure 1B
shows a typical field of sperm tracks; sperm treated with
preimmune IgG swim in progressive straight lines (similar to
those shown in Fig. 1A), whereas sperm treated with anti-eppin
antibodies lose their progressive motility (see online Supple-
mental Movies 1 and 2 available at www.biolreprod.org).
FIG. 2. Cyclic AMP in human spermato-
zoa treated with anti-eppin antibodies from
infertile male monkeys. A) Recovery of
motility by anti-eppin antibody-treated
spermatozoa in the presence of added
cAMP-AM. Total distance (Total Dist.),
straight distance (Straight Dist.), and veloc-
ity (Mean Vel.) increase as tortuosity de-
creases. Data are from a single ejaculate
collected from a typical experiment from
different donors (n ¼ 3). B) Five normal
swim-up samples from fertile donors were
treated with monkey sample no. 523/602 or
523/619 anti-eppin antibodies. After 2 h,
spermatozoa had lost their motility (except
for antibody from monkey sample no. 523/
602 in experiment 5) and were measured
for picomoles of cAMP per 107 spermato-
zoa (6 SD). Antibody-treated samples that
lost their motility were significantly different
from buffer control or preimmune-treated
samples (except for antibody from monkey
sample no. 523/602 in experiments 1 and
5). Buffer control and preimmune samples
are not significantly different from one
another. Combined experiments graph (n ¼
5) shows (6 SEM) that both antibodies are
significantly different from controls. Ab,
antibody; P, P value.
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Human sperm require adenylyl cyclase (ADCY10), cAMP,
Ca2
þ
, and the appropriate intracellular pH for normal forward
motility [15–17], implying that one or more of these
components may have been disrupted by the antibody
treatments. Moreover, disruption of the mouse gene for soluble
adenylyl cyclase (Adcy10) or the sperm-specific Naþ/Hþ
exchanger (Slc9a10) results in spermatozoa that exhibit
impaired motility that could be rescued by cAMP [10, 16].
Therefore, we tested whether anti-eppin-treated spermatozoa
could be rescued by cAMP. Approximately 25% of sperma-
tozoa that have lost their motility from anti-eppin antibody
treatment can be rescued. If spermatozoa are preloaded with
cAMP-AM for 20 min and then treated with monkey anti-eppin
antibody, their loss of forward progress is delayed 30–45 min
(antibody from monkey sample no. 523/619: mean 6 SD
tortuosity, 2.2 6 1.2 for cAMP-AM loaded vs. 10.6 6 12.4 for
nonloaded control). In additional experiments, spermatozoa are
loaded with cAMP-AM 30 min and 60 min after being treated
with monkey anti-eppin antibody, and their motility was
examined 75 min after the initial antibody treatment. These
spermatozoa exhibit significant signs of recovery. As shown in
Figure 2A, monkey anti-eppin antibody-treated spermatozoa
treated with cAMP-AM increased their total distance traveled
4.4-fold, their straight distance traveled 12.1-fold, and their
velocity 4.9-fold, all significant signs of resumed forward
motility. Similarly, their tortuosity decreased 2.5-fold (P ¼
0.01). Their resumed forward motility can be seen in the sperm
tracks shown in Figure 1, C and D, where the lack of forward
progress after antibody treatment for 1 h (Fig. 1C) is replaced
with a straight-line track (Fig. 1D) with the addition of cAMP-
AM. These results indicate that anti-eppin antibodies bound to
eppin on the sperm surface block the ability of the sperm to
regulate its motility; however, addition of exogenous cAMP-
AM can rescue the motility of some spermatozoa within the
time frame that would otherwise produce immotile sperm.
To examine why this was not the case for a larger
percentage of the population of spermatozoa, we measured
cAMP levels in spermatozoa 2 h after anti-eppin antibody
treatment. As shown in Figure 2B, five experiments from
different semen donors revealed that anti-eppin treatment of
spermatozoa significantly increased the amount of cAMP
present in 107 spermatozoa (combined experiments, n ¼ 5).
After treatment with either of these two monkey anti-eppin
antibodies, none of the spermatozoa remain motile (except for
monkey sample no. 523/602 in experiment 5 (25% motile).
Taken together, these cAMP data demonstrate that anti-eppin-
treated spermatozoa have variable cAMP levels (25% of which
can be rescued), implying that disruption of their progressive
motility inhibits their ability to utilize cAMP.
Eppin has previously been shown to bind the seminal fluid
protein semenogelin on the sperm surface in vivo and
recombinant semenogelin in vitro [4, 18]. During contraception
[1], the monkey anti-eppin antibodies would have been
expected to bind to eppin in the epididymis before the
spermatozoa were exposed to seminal fluids. Therefore, we
tested the hypothesis that anti-eppin antibodies bound to eppin
would subsequently block semenogelin binding to eppin. We
used an in vitro assay to measure eppin-semenogelin binding
(see Materials and Methods), and Figure 3A shows the effect
of affinity-purified rabbit anti-recombinant eppin on eppin-
semenogelin binding. As the antibodies are diluted, the binding
of eppin to semenogelin increases. Similarly, Figure 3B shows
that anti-eppin antibodies from two infertile monkeys, monkey
sample nos. 523/625 and 145/656, inhibit eppin from binding
to semenogelin. As the antibody is diluted, more eppin binds to
semenogelin, and the OD increases.
Semenogelin contains a sperm motility inhibitory factor,
which has been identified as amino acids 45–136 of the N-
terminal of semenogelin [19–24]. Cleavage of semenogelin by
PSA during liquefaction removes semenogelin from the sperm
surface, resulting in progressive sperm motility. As summa-
rized in Table 3, addition of semenogelin (containing amino
FIG. 3. A) In vitro assay of eppin-semenogelin binding. Rabbit affinity-
purified anti-eppin antibody inhibits semenogelin (SEMG1) binding to
eppin. The positive control was SEMG1 with eppin with no antibody
present. The negative control was SEMG1 without eppin with no antibody
present. As the antibody is diluted, eppin-SEMG1 binding increases. B)
Contraceptive antibodies from infertile male monkeys (monkey sample
nos. 523/625 and 145/656) inhibit eppin-SEMG1 binding; as the antibody
is diluted, eppin-SEMG1 binding increases. Error bars indicate 6 SD. ep,
eppin; m, monkey; O.D., optical density.
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acid residues 5–365) to progressively motile spermatozoa has a
concentration-dependent inhibitory effect on human sperm
progressive motility as measured by increased tortuosity (7.4
vs. 1.6 in the control, P ¼ 0.0164). Velocity decreases ranged
from 13% to 53% for treatment of sperm from different donors
(n¼ 3; range, P¼ 0.01 to P¼ 2.4 3 1013). Figure 1E shows a
typical video frame of sperm tracks 60 min after treatment with
recombinant human semenogelin. Recorded at 8 frames/sec for
10 sec, progressive straight trajectories and nonprogressive
(very short) path lengths can be seen, presumably because
individual spermatozoa must bind a critical amount of
recombinant human semenogelin (Table 3) to reduce the
distances traveled and to decrease their velocities.
Tracks from anti-eppin antibody-treated sperm and seme-
nogelin-treated sperm can be distinguished from progressive
hyperactivated sperm tracks. Recording at slower frame rates
for longer periods allows better visualization of the hyper-
activated pattern. Two hyperactivated sperm tracks are shown
in Figure 1F, recorded at 8 frames/sec for 10 sec. These can be
distinguished from the progressive straight track in the center
of the field. Hyperactivated tracks are usually a combination of
sharp directional changes and tight circles [25, 26]. In Figure
1F, the straight-line track has a tortuosity value of 1.05 (track
3) and may be compared with the progressive hyperactivated
tracks (tracks 1 and 2), which have tortuosity values of 7.91
(linearity, 13%) and 8.41 (linearity, 12%) respectively, similar
to those reported previously for human hyperactivated
spermatozoa [12].
Monkey anti-eppin and rabbit anti-eppin antibodies inhibit
eppin-semenogelin binding as already described, and semeno-
gelin has been shown to bind to the C-terminal amino acids 76–
133 of eppin [4]. Moreover, the dominant specific epitopes of
these anti-eppin antibodies have been determined [1, 5]; the
contraceptive C-terminal epitope of eppin was found to be
amino acids 101–125 (TCSMFVYGGCQGNNNNFQ
SKANCLN). Therefore, we prepared affinity-purified rabbit
antibodies to amino acids 103–123 in this epitope (antibody
S21C) to test whether it would have effects similar to those of
treatment with recombinant human semenogelin. Similar to the
addition of recombinant human semenogelin to progressively
motile spermatozoa, addition of antibody S21C had an
inhibitory effect on human sperm progressive motility as
measured by increased tortuosity (2.5 vs. 1.5 in the control, P¼
0.006, two experiments from two different donors, n ¼ 160),
decreased velocity (18%, P ¼ 5.42 3 105, n ¼ 160) and by
decreased straight distance (18%, P ¼ 0.007, n ¼ 160).
DISCUSSION
Contraceptive anti-eppin antibodies from male monkeys in
our previous study [1] inhibit human sperm progressive
motility. The antibodies significantly decrease sperm velocity
and the distance they travel, increasing the curvilinear
distance:straight distance ratio (tortuosity). The antibodies
from individual infertile monkeys are polyclonal, with each
individual’s antibodies recognizing slightly different eppin
epitopes yet all having common dominant epitopes [1]. This
may explain the individual differences in the abilities of the
antibodies to inhibit progressive motility, as summarized in
Table 1. Future studies will focus on specific epitopes.
The contraceptive anti-eppin antibodies seem to disrupt the
cAMP regulatory pathway of the sperm. The production of
cAMP by adenylyl cyclase (soluble adenylyl cyclase [27])
requires HCO
3
 and Ca2þ [15, 17, 28], and loss of progressive
motility can be directly correlated with loss of cAMP from
inactivation of the mouse Adcy10 gene [10]. Similarly,




exchanger (Slc9a10) results in spermatozoa with impaired
motility [16]. Progressive motility may be recovered after
inactivation of the Adcy10 or Slc9a10 gene by loading
spermatozoa with cAMP-AM [10, 16, 29]. In the present
study, we found that treatment of human spermatozoa with
anti-eppin antibodies resulted in a significant increase in cAMP
levels in the treated population of spermatozoa, although
approximately 25% of these spermatozoa could be rescued by
addition of the cAMP analogue cAMP-AM. Increased cAMP is
generally associated with increased motility [17, 30]; therefore,
the loss of progressive motility after anti-eppin treatment must
have been the result of a downstream disruption in the cAMP
pathway, resulting in an inability to utilize the cAMP.
Inhibition of phosphodiesterase activity would result in
increased cAMP levels; however, this would be predicted to
increase motility [30]. Increased cAMP levels should have
evoked increased Ca2
þ
entry, which also would be predicted to
increase motility [30]. Although the three critical components
required for motility, namely, cAMP, Ca2
þ
, and pH, may have
been disrupted by the anti-eppin treatment, the finding that
cAMP levels were elevated for the population of treated
spermatozoa without subsequent increased motility suggests
the intriguing possibility that coating the surface of the
spermatozoon with antibody may cause loss of regulation of





role in the compartmentalized control of flagellar pH as
suggested by Wang et al. [31], then the slow decline in
progressive motility in antibody-treated sperm may reflect a
slow decrease in flagellar pH. This idea is supported by the
observations that 1) outer dynein arm activity is pH dependent
and requires alkalinization, as well as Ca2
þ
and cAMP-
dependent phosphorylation [32, 33]; 2) flagella bending is pH
dependent [26]; and 3) cAMP is necessary for flagella bending
in a 7.9 pH environment [34]. In addition, it is possible that the
free diffusion of lactate into the surrounding medium following
conversion from pyruvate [35] might be blocked by antibody
binding, decreasing the flagellar pH. Further experiments will
be necessary to test this hypothesis.
The role of semenogelin during ejaculation has been
reviewed by Robert and Gagnon [8]. In the efferent ducts
and epididymis before ejaculation, eppin is localized on the
entire surface of spermatozoa [2]. Upon ejaculation, semeno-
gelin is added from the seminal vesicles and binds to eppin
within the coagulum and on the sperm surface [4]. Eppin
completely covers the sperm surface, and most recently we
have shown that an eppin protein complex containing
lactotransferrin, clusterin, and semenogelin is localized on the
sperm tail [3]. To our knowledge, monkey anti-eppin
antibodies have not been used to detect eppin by immunoflu-
orescence on human spermatozoa. During liquefaction, seme-
nogelin must be removed from the sperm surface [8] because it
is a natural inhibitor of human sperm progressive motility [19–
24, 36], and in this study we demonstrated that recombinant
human semenogelin inhibits human sperm progressive motility.
Using semenogelin I purified from semen, Yoshida et al. [36]
demonstrated that treatment of spermatozoa with semenogelin
decreased the straight-line velocity and linearity of human
spermatozoa. Our previous observation that reduction and
carboxymethylation of the only cysteine of semenogelin inhibit
its binding to eppin [4] has been confirmed by mutation of the
semenogelin amino acid cysteine; mutant recombinant human
semenogelin does not bind eppin and removes the ability of
recombinant human semenogelin to inhibit progressive motility
(A. Mitra, personal communication).
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Our demonstration that contraceptive antibodies to eppin
that inhibit sperm motility also inhibit semenogelin binding to
eppin (Fig. 3) suggests that eppin-semenogelin binding is a key
step in regulating sperm motility. The inhibition of motility by
anti-eppin antibodies directed toward the C-terminal contra-
ceptive epitope of eppin on the surface of spermatozoa
confirms the importance of this site in regulating motility.
Consequently, we conclude from our studies that the eppin-
semenogelin binding site is the key interaction site for the loss
of semenogelin binding and for the initiation of progressive
motility in vivo after liquefaction. It is also the key site for the
inhibition of progressive motility by anti-eppin antibodies. This
epitope is at least partially engaged in binding semenogelin
because mutant semenogelin that does not bind eppin does not
affect progressive motility. Our results (Fig. 1 and Table 2)
support our previous hypothesis [5] that the effect of having
anti-eppin antibodies on the surface of spermatozoa mimics the
physiological effect of having the sperm motility inhibitor
semenogelin bound to the surface. As a result of our analysis of
the contraceptive effect of anti-eppin antibodies on human
spermatozoa, we conclude that the eppin-semenogelin binding
site on the surface of human spermatozoa is an ideal target for a
nonsteroidal male contraceptive.
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